Vivus Obesity Pill Scores With Phase III Data, But Still Faces Major Market Hurdles
This article was originally published in The Pink Sheet Daily
Executive Summary
Qnexa combines two generics, but Vivus Chief Operating Officer Peter Tam says: "We are not concerned about generic substitution."